TSC2 and tuberous sclerosis: <i>In vivo</i>, this combination alleviated renal impairment in <i>Tsc1</i>- or <i>Tsc2</i>-deficient models, suggesting a promising therapeutic strategy for TSC patients with suboptimal response to mammalian target of rapamycin complex 1 (mTORC1) inhibitors.